Research has been conducted on the assessment of PD-L1 expression in gastric cancer using various antibodies. There appear to be discrepancies among different PD-L1 assays used in gastric cancer, which may have implications for patient treatment and biopsy-site choice. The relationship between PD-L1 expression and patient outcomes, such as overall survival, is also being studied in various populations.